Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102 in Wet Age-Related Macular Degeneration and Accelerates Trial Read-out by Approximately Six Months
March 18, 2020 07:00 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the...
Graybug Vision Presents Preclinical Results for GB-401, a Potential Sustained-Delivery Treatment of up to Six Months for Primary Open Angle Glaucoma, at the American Glaucoma Society Annual Meeting
February 28, 2020 07:00 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic...
Optovue Highlights World’s First OCTA Metrics and Corneal Measurement Method at AAO 2018
October 25, 2018 09:00 ET
|
Optovue, Incorporated
Blood Vessel Measurement Technology Helps Doctors Manage Eye Diseases CHICAGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Optovue, the global leader in the development of optical coherence tomography (OCT)...
GrayBug, LLC Appoints Michael O'Rourke as President & CEO
October 28, 2013 11:32 ET
|
GrayBug
BALTIMORE, Oct. 28, 2013 (GLOBE NEWSWIRE) -- GrayBug, LLC, a company that focuses on the development of innovative injectable drug delivery systems to more effectively treat eye diseases, has...